RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @jpcostabel: Nuevo metaanálisis de drogas antidiabéticas parece mostrar una superioridad de los inhibidores de SGLT 2 sobre los agonista…
RT @jpcostabel: Nuevo metaanálisis de drogas antidiabéticas parece mostrar una superioridad de los inhibidores de SGLT 2 sobre los agonista…
RT @jpcostabel: Nuevo metaanálisis de drogas antidiabéticas parece mostrar una superioridad de los inhibidores de SGLT 2 sobre los agonista…
RT @jpcostabel: Nuevo metaanálisis de drogas antidiabéticas parece mostrar una superioridad de los inhibidores de SGLT 2 sobre los agonista…
RT @jpcostabel: Nuevo metaanálisis de drogas antidiabéticas parece mostrar una superioridad de los inhibidores de SGLT 2 sobre los agonista…
RT @jpcostabel: Nuevo metaanálisis de drogas antidiabéticas parece mostrar una superioridad de los inhibidores de SGLT 2 sobre los agonista…
RT @jpcostabel: Nuevo metaanálisis de drogas antidiabéticas parece mostrar una superioridad de los inhibidores de SGLT 2 sobre los agonista…
RT @jpcostabel: Nuevo metaanálisis de drogas antidiabéticas parece mostrar una superioridad de los inhibidores de SGLT 2 sobre los agonista…
RT @jpcostabel: Nuevo metaanálisis de drogas antidiabéticas parece mostrar una superioridad de los inhibidores de SGLT 2 sobre los agonista…
RT @jpcostabel: Nuevo metaanálisis de drogas antidiabéticas parece mostrar una superioridad de los inhibidores de SGLT 2 sobre los agonista…
RT @jpcostabel: Nuevo metaanálisis de drogas antidiabéticas parece mostrar una superioridad de los inhibidores de SGLT 2 sobre los agonista…
Nuevo metaanálisis de drogas antidiabéticas parece mostrar una superioridad de los inhibidores de SGLT 2 sobre los agonistas GLP1. Tendremos que hacer estas comparaciones indirectas o existirá alguna vez un estudio que los compare?https://t.co/SCNEYJaBmx h
RT @ash71us: SGLT2 blockers need to be prescribed by cardiologists. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Ty…
SGLT2 blockers need to be prescribed by cardiologists. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes https://t.co/xVnAq8bxaD
RT @almucastro01: El cambio del paradigma sigue su camino: cada vez más preocupación en Cardiología por la DM y sus complicaciones. En este…
RT @almucastro01: El cambio del paradigma sigue su camino: cada vez más preocupación en Cardiología por la DM y sus complicaciones. En este…
RT @almucastro01: El cambio del paradigma sigue su camino: cada vez más preocupación en Cardiología por la DM y sus complicaciones. En este…
RT @almucastro01: El cambio del paradigma sigue su camino: cada vez más preocupación en Cardiología por la DM y sus complicaciones. En este…
RT @almucastro01: El cambio del paradigma sigue su camino: cada vez más preocupación en Cardiología por la DM y sus complicaciones. En este…
RT @almucastro01: El cambio del paradigma sigue su camino: cada vez más preocupación en Cardiología por la DM y sus complicaciones. En este…
El cambio del paradigma sigue su camino: cada vez más preocupación en Cardiología por la DM y sus complicaciones. En este artículo del JACC HF se analizan los nuevos AD y su relación con la IC https://t.co/s06YpUTQuk @domingomarzal @Dr_Manito https://t.co
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
@ManuRiveraMD Network!
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
It is looking like a vascular drug
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @JACCJournals: New network meta-analysis by a Toronto team shows SGLT-2 inhibitors are more effective than GLP-1 receptor agonists or DP…
RT @EmtiroHealth: JACC meta-analysis of 9 studies suggests that SGLT-2 inhibitors are more effective than either GLP-1 agonists or DPP-4 in…
JACC meta-analysis of 9 studies suggests that SGLT-2 inhibitors are more effective than either GLP-1 agonists or DPP-4 inhibitors for reducing the risk of hospitalization for HF in type 2 diabetes mellitus. https://t.co/bDRlCZRRJm
RT @Epocrates: SGLT-2 inhibitors better at preventing HF in T2DM, according to @JACCJournals https://t.co/2NOZvRdMuO https://t.co/kRWspPKd…
RT @Epocrates: SGLT-2 inhibitors better at preventing HF in T2DM, according to @JACCJournals https://t.co/2NOZvRdMuO https://t.co/kRWspPKd…
SGLT-2 inhibitors better at preventing HF in T2DM, according to @JACCJournals https://t.co/2NOZvRdMuO https://t.co/kRWspPKdwc
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @Diabetes_SEMI: Metanalisis para este domingo: Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes. ht…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
Mi still loving them 😍
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
https://t.co/sTXhJkSguT SGLT2 inhibitors again showing their worth in reducing HF hospital admission. https://t.co/6gs5dkpeoq
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
RT @vic_pallares: Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current eviden…
Comparison of New Glucose-Lowering Drugs on Risk of #HeartFailure in #T2DM -> for reducing the risk of HF, current evidence favors the choice of SGLT2i ->practitioners might consider when reviewing HF risks in the management of T2DM in clinical pract
RT @Diabetes_SEMI: Metanalisis para este domingo: Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes. ht…
RT @realjosullivan: Sglt2 on top @gemtreee @carmine_3Dheart https://t.co/Q2RLzrkaT7
RT @paomorejon: Comparación entre GLP-1; DPP-4; SGLT-2i y riesgo de #InsuficienciaCardiaca en pacientes con #Diabetes tipo2 • Meta-análisi…
Sglt2 on top @gemtreee @carmine_3Dheart
RT @DanielJDrucker: Are network analyses useful to understand which drugs #diabetes reduce #heartfailure hospitalization? https://t.co/Agbf…
RT @DanielJDrucker: Are network analyses useful to understand which drugs #diabetes reduce #heartfailure hospitalization? https://t.co/Agbf…
Are network analyses useful to understand which drugs #diabetes reduce #heartfailure hospitalization? https://t.co/AgbfNEWvHd
RT @Diabetes_SEMI: Metanalisis para este domingo: Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes. ht…
RT @Office_j: 【プラセボ対照ランダム化試験9報 [87162例] ネットワークメタ解析:SGLT2阻害薬で、GLP-1アナログに比べ、心不全入院RRは0.59 [95%CI 0.43-0.79]。対DPP4阻害薬なら0.50 [0.36-0.70]】 JACC…
RT @CarlosGR82: Parece q esta claro q ante paciente diabético con insuficencia cardiaca.. Los isglt2 estan por delante del resto de antidia…
RT @Diabetes_SEMI: Metanalisis para este domingo: Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes. ht…
RT @CarlosGR82: Parece q esta claro q ante paciente diabético con insuficencia cardiaca.. Los isglt2 estan por delante del resto de antidia…
Parece q esta claro q ante paciente diabético con insuficencia cardiaca.. Los isglt2 estan por delante del resto de antidiabeticos orales.. Pendientes del Declare #DiabetESP
SGLT - 2 inhibitors reduce the rate of Heart Failure hospitalizations https://t.co/3oBYwqWLUr
RT @Diabetes_SEMI: Metanalisis para este domingo: Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes. ht…
RT @Diabetes_SEMI: Metanalisis para este domingo: Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes. ht…
Metanalisis para este domingo: Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes. https://t.co/MNZ5NJVOvj https://t.co/zny4667x3b
RT @paomorejon: Comparación entre GLP-1; DPP-4; SGLT-2i y riesgo de #InsuficienciaCardiaca en pacientes con #Diabetes tipo2 • Meta-análisi…
RT @paomorejon: Comparación entre GLP-1; DPP-4; SGLT-2i y riesgo de #InsuficienciaCardiaca en pacientes con #Diabetes tipo2 • Meta-análisi…
RT @paomorejon: Comparación entre GLP-1; DPP-4; SGLT-2i y riesgo de #InsuficienciaCardiaca en pacientes con #Diabetes tipo2 • Meta-análisi…